Copyright
©The Author(s) 2020.
World J Gastroenterol. Aug 14, 2020; 26(30): 4501-4522
Published online Aug 14, 2020. doi: 10.3748/wjg.v26.i30.4501
Published online Aug 14, 2020. doi: 10.3748/wjg.v26.i30.4501
Treatment response | Treatment (ICE) group (n = 199) | Control group ( n = 196) | χ2/Z | P value |
48 wk | ||||
Patients with HBV DNA level decline > 2 log10 IU/mL, n (%) | 30 (15.08) | 13 (6.63) | 7.255 | 0.007 |
Patients with HBV DNA level ≤ 4 log10 IU/mL, n (%) | 20 (10.05) | 5 (2.55) | 9.367 | 0.002 |
Patients with undetectable HBV DNA (≤ 20 IU/mL), n (%) | 2 (1.01) | 0 (0.00) | 1.980 | 0.159 |
96 wk | ||||
Patients with HBV DNA level decline > 2 log10 IU/mL, n (%) | 60 (30.15) | 12 (6.12) | 38.249 | 0.000 |
Patients with HBV DNA level ≤ 4 log10 IU/mL, n (%) | 37 (18.59) | 6 (3.06) | 24.555 | 0.000 |
Patients with undetectable HBV DNA (≤ 20 IU/mL), n (%) | 4 (2.01) | 0 (0.00) | 2.227 | 0.136 |
- Citation: Xing YF, Wei CS, Zhou TR, Huang DP, Zhong WC, Chen B, Jin H, Hu XY, Yang ZY, He Q, Jiang KP, Jiang JM, Hu ZB, Deng X, Yang F, Li FY, Zhao G, Wang LC, Mi YQ, Gong ZJ, Guo P, Wu JH, Shi WQ, Yang HZ, Zhou DQ, Tong GD. Efficacy of a Chinese herbal formula on hepatitis B e antigen-positive chronic hepatitis B patients. World J Gastroenterol 2020; 26(30): 4501-4522
- URL: https://www.wjgnet.com/1007-9327/full/v26/i30/4501.htm
- DOI: https://dx.doi.org/10.3748/wjg.v26.i30.4501